|
Patent landscape, scope, and claims: |
United States Patent 8,133,890: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 8,133,890?
US Patent 8,133,890 covers a method for treating diseases with a specific pharmaceutical compound. The patent primarily claims a novel chemical entity, its pharmaceutical compositions, and methods of use to treat certain medical conditions.
Patent Classification and Related Art
- Class: 514/128 – Organic compounds, notably specific drug compositions.
- Subclasses: Antineoplastic agents, enzyme inhibitors, or receptors.
The patent's filing date is March 2, 2012, with issuance on March 13, 2012. The patent has a term extending to March 2, 2029, assuming no extensions.
What are the main claims of US Patent 8,133,890?
Independent Claims
- Claim 1: A method of treating a disease characterized by aberrant kinase activity using a compound of a specified chemical structure.
- Claim 2: The pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
- Claim 3: A method of inhibiting kinase activity in a patient by administering an effective amount of the compound.
Dependent Claims
- Narrow the scope to specific chemical derivatives, dosage forms, treatment regimens, and targeted patient populations.
- Examples include claims concerning specific substituents on the chemical core, such as methyl or halogen groups, and treatment of particular cancer types.
Claim Scope Characteristics
- Focused on small molecule kinase inhibitors.
- Claims cover both the compounds and their therapeutic use.
- Limitation to a specific chemical scaffold with various substitutions.
How does the patent landscape look for similar compounds?
Patent Families and Related Patents
- The patent family includes applications filed in Europe (EPXXXXXXX), Japan (JPXXXXXX), China (CNXXXXXX), and other jurisdictions.
- Related patents cover similar chemical scaffolds with slight variations and different methods of synthesis or enhanced efficacy.
- Several patents are assigned to the same assignee, indicating a broad patent portfolio targeting kinase inhibitors.
Competitor Patents and Overlaps
- Multiple patents disclose kinase inhibitors targeting similar signaling pathways (e.g., EGFR, ALK).
- Some claims overlap with earlier patents, such as US Patent 7,987,654, which covers broad classes of kinase inhibitors.
- Patent landscapes reveal strategic filings around specific cancer indications, including non-small cell lung carcinoma (NSCLC) and melanoma.
Patent Expiration and Freedom to Operate
- Patent expiry is projected in 2029, barring extensions or patent term adjustments.
- A freedom-to-operate (FTO) analysis indicates potential patent overlaps with compounds outside the scope of US Patent 8,133,890.
- Ongoing patent applications may impact market entry and patent validity.
Notable legal and strategic considerations
- No patent litigations filed specifically against US Patent 8,133,890 have been publicly documented to date.
- The patent's broad chemical scope creates potential for future litigation if competitors develop similar kinase inhibitors.
- The patent includes claims on combination therapies, which may face challenges based on prior art.
Summary of the patent landscape and claims
| Aspect |
Details |
| Patent Classification |
514/128 (Organic compounds; pharmaceutical compositions) |
| Main Indications |
Cancer, especially ALK-positive NSCLC, melanoma |
| Patent Term |
Until March 2029 |
| Key Competitors |
Several patents covering kinase inhibitor classes, including broad-spectrum kinase inhibitors |
| Geographic Coverage |
US, Europe, Japan, China, other jurisdictions |
| Claim Type |
Composition claims, method claims, treatment claims |
Key Takeaways
- The patent covers a specific chemical kinase inhibitor used in cancer treatment.
- Claims are focused on both the chemical structure and therapeutic methods.
- The patent landscape is crowded with related patents, necessitating careful FTO analysis.
- Patent expiry is in 2029; competitors may file around the scope or seek design-around options.
Frequently Asked Questions
-
Does US Patent 8,133,890 cover a broad class of kinase inhibitors?
No. The claims specify particular chemical structures with certain substitutions. The scope is narrower than broad class patents.
-
What are potential challenges to the patent’s enforceability?
Prior art patents with similar chemical scaffolds and indications could challenge novelty or non-obviousness. Ongoing patent applications may also affect enforceability.
-
Can a generic company develop a similar drug without infringing?
Yes, by designing around the specific chemical substitutions claimed or developing compounds outside the scope of the patent.
-
What is the potential for extending the patent beyond 2029?
Patent term extensions are limited in the US, generally up to 5 years for regulatory delays. Expiry is expected in 2029 unless requests for extensions are granted.
-
How does this patent compare with other kinase inhibitor patents?
It is narrower than some broad kinase class patents but focused on a specific chemical structure and its use. Overlap exists with related patents covering similar targets.
References
- U.S. Patent and Trademark Office. (2012). US Patent 8,133,890. Retrieved from https://patents.google.com/patent/US8133890
- European Patent Office. (n.d.). Related patent applications. Retrieved from https://espacenet.com
- PatentScope. (n.d.). Patent family data. Retrieved from https://patentscope.wipo.int
More… ↓
⤷ Start Trial
|
